News and research before you hear about it on CNBC and others. Claim your one…
News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.
LAS VEGAS, June 16, 2022 (GLOBE NEWSWIRE) — Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that human test subjects in its first-in-man research study for the treatment of Parkinson’s disease, at mid-30, had a 50% improvement in motor skills. Zhittya’s study used its biologic drug candidate human FGF-1 in conjunction with a proprietary intranasal delivery device to deliver its drug into the brain. Previous preclinical work has established that twice the amount of FGF-1 can be delivered to the brain intranasally compared to intravenously. Intranasal dosing began in human test subjects on May 3, 2022 and ended on May 30, 2022 with patients receiving two escalating doses of intranasal FGF-1. No adverse events to date have been observed among the subjects and analysis of videos taken before and after treatment showed promising signs of improvement in motor skills, according to the subjects tested and the principal investigator supervising the test. Additional follow-up sessions will take place 60 days and 90 days after treatment to assess any adverse events that may have occurred and to document any continued progress towards reversing the test subjects’ Parkinson’s disease.
Zhittya will host a free Zoom webinar titled: Medical research study in Parkinson’s disease: first look at data from intranasal administration of FGF-1. This webinar will air at 3:00 p.m. PT on Thursday, June 23, 2022. Viewers will learn about the results of this completed research study and will be able to see first-hand data on the safety and efficacy tests collected . so far. To register for the webinar, please visit the company’s website: zgm.care.
Daniel Montano, CEO of Zhittya Genesis Medicine, said, “I was there the first day when the test subjects were dosed and I was with them on the last day of their dosing. Based on our previous clinical data on the use of FGF-1 to treat advanced coronary artery disease, as well as preclinical data testing FGF-1 in a primate model of Parkinson’s disease, I expected very little progress in test subjects within the first 30 days. We believe that the process of angiogenesis will take 3-8 weeks to initiate and complete, at which time the process of neurogenesis will occur over the next 4-12 weeks. So I was pleasantly shocked by the improvement I witnessed in the test subjects. Please join us for our Zoom webinar on June 23 where you can see this videotaped data with your own eyes and also hear the test subjects themselves. We are still in the early stages of discovering the best dose, the best duration of treatment, etc., however, I believe we are well on our way to addressing and solving the problems of Parkinson’s disease for millions. of people.
Over the past five years, a new medical hypothesis has been proposed that Parkinson’s disease may be triggered by vascular disruption in areas of the brain that house dopamine-producing neurons. The theory holds that over time, the micro-vasculature in the brain becomes blocked, shrinks, or leaks, causing blood flow to be restricted, which prevents affected neurons from receiving adequate nourishment. This disruption of a natural biological process can lead to the classic symptoms of Parkinson’s disease, including tremors and difficulty walking. Very promising improvements in motor tests have been observed with FGF-1 in models of Parkinson’s disease in rodents and primates. In these models, FGF-1 has been shown to act as a “disease modifying agent” by regenerating new dopamine-secreting neurons. These neurons become dysfunctional in Parkinson’s disease and are widely recognized as the root cause of the disease.
Dr. Jack Jacobs, President and Chief Scientific Officer of Zhittya Genesis Medicine, said: “Although this initial study was primarily designed to test the safety of FGF-1 administered intranasally, we were pleased to see evidence of improvement of patients, both in terms of physical examinations and filming of motor functions, as well as tests with the standardized questionnaire on Parkinson’s disease. Intranasal administration of FGF-1 is incredibly simple and non-invasive and avoids the use of central catheters (picc lines) that were originally considered for this study. Because of this ease of administration, we are already designing additional research studies where intranasally administered FGF-1 could be examined in other brain disorders, including stroke recovery, vascular dementia, Alzheimer’s disease, Alzheimer’s, aphasia and multiple sclerosis. We also want to expand our studies in patients with Parkinson’s disease to include different dosing regimens and study FGF-1 in patients who have deep brain stimulators (DBS) implanted or whose devices have been removed. I also believe that the safety and efficacy data we gather in these relatively small human research studies will strengthen and enhance the investigational new drug (IND) application that is filed with the US FDA. We hope to be able to begin these human trials in the United States within two years.”
Again, Zhittya’s free Zoom webinar on early human results from our study of intranasal administration of FGF-1 in subjects with Parkinson’s disease will air on June 23, 2022 at 3:00 p.m. PT ( 6 p.m. EST). , go to: zgm.care
About Zhittya Genesis MedicineZhittya Genesis Medicine, Inc. advances a group of drugs that trigger the human body’s natural regeneration process. Our medicine initiates a biological response in the human body called “therapeutic angiogenesis”, which only occurs in diseased tissues that become ischemic due to a lack of blood flow. In areas with poor blood flow, the drug stimulates the growth of new blood vessels, providing nourishment and removing metabolic wastes, thereby restoring normal cell functions. In addition to the brain disorders described above, the company also has promising evidence that FGF-1 is a potential new treatment for coronary heart disease, peripheral arterial disease (PAD) and diabetic foot ulcers. Currently, more than 75 human diseases are known to be caused by a lack of blood flow to a tissue or organ. The company’s management has been dedicated to advancing its proprietary medicines for more than 23 years and has spent more than US$150 million to date to support these efforts. To learn more, please visit: zgm.care
Daniel Montano, CEOZhittya Genesis Medicine, Inc.702-802-8373 [email protected]
Source: Zhittya Genesis Medicine Inc.